兰卫医学
(301060)
| 流通市值：16.06亿 | | | 总市值：35.77亿 |
| 流通股本：1.80亿 | | | 总股本：4.01亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,269,876,218.4 | 837,910,261.21 | 412,587,989.38 | 4,199,305,065.95 |
| 营业收入 | 1,269,876,218.4 | 837,910,261.21 | 412,587,989.38 | 4,199,305,065.95 |
| 二、营业总成本 | 1,202,201,574.29 | 781,246,616.49 | 368,985,556.77 | 3,071,057,436.51 |
| 营业成本 | 958,846,932.08 | 622,494,205.65 | 292,605,731.41 | 2,408,886,257.28 |
| 税金及附加 | 3,425,588.68 | 1,924,333.57 | 961,532.29 | 5,468,906.93 |
| 销售费用 | 69,817,487.13 | 46,386,155.67 | 21,385,761.71 | 184,120,632.96 |
| 管理费用 | 135,354,499.72 | 89,222,413.62 | 42,502,572.94 | 355,540,614.87 |
| 研发费用 | 32,701,057.63 | 19,633,515.29 | 10,753,900.8 | 109,401,528.57 |
| 财务费用 | 2,056,009.05 | 1,585,992.69 | 776,057.62 | 7,639,495.9 |
| 其中:利息费用 | 6,236,207.62 | 3,906,218.23 | 2,178,526.98 | 8,458,391.85 |
| 其中:利息收入 | 4,773,637.34 | 2,656,417.46 | 1,400,302.26 | 2,780,662.32 |
| 加:公允价值变动收益 | - | 0 | 0 | 1,664,161.13 |
| 加:投资收益 | -2,298,039.97 | -1,665,369.86 | -867,042.16 | 748,083.52 |
| 资产处置收益 | 1,500,595.33 | -682,485.88 | -300,952.62 | -363,154.67 |
| 资产减值损失(新) | -8,263,201.8 | -2,699,704.68 | -700,768.12 | -136,371,974.39 |
| 信用减值损失(新) | -74,976,930.81 | -78,349,866.12 | -35,517,924.09 | -54,588,069.05 |
| 其他收益 | 22,034,940.81 | 20,603,847.79 | 16,326,865.98 | 9,939,173.98 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 5,672,007.67 | -6,129,934.03 | 22,542,611.6 | 949,275,849.96 |
| 加:营业外收入 | 200,780.6 | 156,471.57 | 67,546.34 | 1,588,867.93 |
| 减:营业外支出 | 5,358,935.61 | 5,156,173.64 | 2,982,502.98 | 46,421,315.99 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 513,852.66 | -11,129,636.1 | 19,627,654.96 | 904,443,401.9 |
| 减:所得税费用 | 9,881,038.36 | 6,666,777.75 | 4,036,640.25 | 165,388,238.57 |
| 六、净利润 | -9,367,185.7 | -17,796,413.85 | 15,591,014.71 | 739,055,163.33 |
| 持续经营净利润 | -9,367,185.7 | -17,796,413.85 | 15,591,014.71 | 739,055,163.33 |
| 归属于母公司股东的净利润 | -880,075.42 | -1,822,631.04 | 21,413,081.32 | 617,322,755.95 |
| 少数股东损益 | -8,487,110.28 | -15,973,782.81 | -5,822,066.61 | 121,732,407.38 |
| (一)基本每股收益 | 0 | 0 | 0.05 | 1.54 |
| (二)稀释每股收益 | 0 | 0 | 0.05 | 1.54 |
| 九、综合收益总额 | -9,367,185.7 | -17,796,413.85 | 15,591,014.71 | 739,055,163.33 |
| 归属于母公司股东的综合收益总额 | -880,075.42 | -1,822,631.04 | 21,413,081.32 | 617,322,755.95 |
| 归属于少数股东的综合收益总额 | -8,487,110.28 | -15,973,782.81 | -5,822,066.61 | 121,732,407.38 |
| 公告日期 | 2023-10-28 | 2023-08-31 | 2023-04-27 | 2023-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |